ClinicalTrials.gg
CompletedNCT05048875Updated Nov 4, 2026Results posted

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

A Phase 2 interventional study of Cohort 1 - Group 1 JNJ High Dose and Cohort 1 - Group 2 JNJ Medium Dose in Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Prevention

How we know

Updated Nov 4, 2026Study documents postedPosted results revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Dengue by National Institute of Allergy and Infectious Diseases (NIAID) — 1 open to participants now, 1 under way, none of them phase 3. Dengue · National Institute of Allergy and Infectious Diseases (NIAID).

Enrollment
15th of 32
56 · median 56
Started
2022
the only one that year
Phase 2
3 of 35
none open now
Registered
34th of 35
by date

Among the 35 studies in Dengue by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 15th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 2, and was the 34th registered.

Dengue

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

Browse Dengue studies →

Open to participants now

1 of the 35 studies in Dengue by National Institute of Allergy and Infectious Diseases (NIAID) is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Dengue by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a placebo with respect to its antiviral activity in healthy adult participants inoculated with Dengue Serotype 3.

Read the detailed description

This study is a multicenter, randomized, placebo-controlled, double-blind, interventional Phase 2a, study in normal healthy adult subjects 18 - 55 years of age, inclusive, recruited from the metropolitan Baltimore/Washington, DC area \& Burlington/Vermont. The study follows an adaptive 2-stage design consisting of 2 cohorts, each with up to 3 groups. The 2 cohorts will be enrolled in a staggered manner. As a safety measure, a sentinel group of 4 participants will be enrolled in Cohort 1 (Group 1a) before enrolling the remaining participants (Group 1b and Group 2) in the cohort.

The purpose of this study is to evaluate the clinical and virologic response to repeated doses of investigation product JNJ-64281802 when administered orally in healthy, DENV and ZIKV-naïve, non-pregnant, adult volunteers who are subsequently inoculated with rDEN3delta30, a recombinant DENV-3 strain, to explore the antiviral activity of repeated oral doses of JNJ-64281802 versus placebo. The safety, tolerability, PK, and the relationship between the PK and antiviral activity of JNJ-64281802 will also be evaluated. Placebo recipients are included in the study as a control to better assess study agent associated versus non-study agent associated AEs and to act as infectivity controls following administration of rDEN3delta30.

After providing written informed consent, subjects will undergo eligibility screening, including medical history, physical examination, hematology testing, liver and renal function testing, human immunodeficiency virus (HIV) screening, hepatitis B and C screening, urinalysis, urine toxicology screening, ECG screening, alcohol breath test screening (per PI/provider discretion), COVID-19 testing (if determined necessary by the clinician or per guidelines), and serology screening for previous infection of DENV and ZIKV (Cohort 1) and DENV, ZIKV, West Nile virus, and SLEV (Cohort 2).

Serum or urine pregnancy testing will be performed on applicable persons of childbearing potential. All screening tests must be performed within 60 days of initiation of JNJ-64281802 study agent at Study Day -5 (Cohort 1) or Study Day -2 (Cohort 2). HIV screening must be performed within 2 weeks of JNJ-64281802 study agent administration. Pregnancy screening will occur at applicable screening visit(s), be repeated on the first day of JNJ-64281802 administration prior to administration, and on the day of inoculation with rDEN3delta30 prior to inoculation with rDEN3delta30. All clinically significant abnormalities will be reviewed with subjects and referral for follow-up care will be provided. Subjects will be determined to be eligible based on the inclusion and exclusion criteria for this protocol. For subjects who are eligible, the Study Day -5 (Cohort 1) or Study Day -2 (Cohort 2) visit will be scheduled for initiation of JNJ-64281802.

For Cohort 1: Subjects will present to the inpatient unit on Study Day -6. After eligibility criteria have been reviewed and confirmed, subjects will be admitted during this period of intensive PK sampling. Dosing with JNJ-64281802 or placebo will begin on Study Day -5. Discharge will occur on Study Day -4. Dosing with JNJ-64281802 will be observed in-clinic on Days -5, -4, -1, 1, 3, 5, 7, 9, 11, 14, 16, 18, and 21. Subjects will have phone contact on Days -3, -2, 2, 4, 6, 8, 10, 12, 13, 15, 17, 19, and 20 to record time of dose, time of last food intake, and review AEs and concomitant therapy. Daily dosing with JNJ-64281802 or placebo will occur from Study Day -5 through Study Day 21. On Study Day 21 subjects will present to the unit for a second intensive PK sampling period for a full day. On Study Day 1, all subjects will be challenged with rDEN3delta30.

For Cohort 2: Subjects will present to the inpatient unit on Study Day -3. After eligibility criteria have been reviewed and confirmed, subjects will be admitted during this period of intensive PK sampling. Dosing with JNJ-64281802 or placebo will begin on Study Day -2. Discharge will occur on Study Day 1. Dosing with JNJ-64281802 will be observed in-clinic on Days -2, -1, 1, 4, 6, 8, 11, 13, 15, 18, and 21 for the daily dosing regimen and on Days -2, -1, 1, 8 and 15 for the weekly dosing regimens. In the daily dosing regimen with JNJ-64281802 or placebo, twice daily dosing will occur from Study Day -2 to Study Day -1, and daily dosing from Study Day 1 to Study Day 21. In the weekly dosing regimens, twice daily dosing will occur from Study Day -2 to Study Day -1, and weekly dosing which will occur on Study Day 1, Study Day 8, and Study Day 15. On Study Day 21 for the daily regimen, and on Study Day 15 for the weekly regimens, subjects will present to the unit for a second intensive PK sampling period for a full day. On Study Day 1, all subjects will be challenged with rDEN3delta30.

During the inpatient visits on Study Day -6 to -4 (Cohort 1) and Study Day -3 to 1 (Cohort 2), the subjects will be evaluated by a clinician and will have blood drawn for clinical laboratory studies, virologic assays, and immunologic assays. During the outpatient visits subjects will return to the clinic for evaluation and for blood draw as specified in the Schedule of Procedures. Study Day 85 will be the final visit for Cohort 1. Study Day 85 will be the final visit for Cohort 2*. Subjects will have their temperature measured in clinic or measure their temperatures at home twice daily from Study Day 1 through Study Day 29.

03

Conditions studied

  • Dengue

Browse trials for

Keywords

  • Dengue Serotype 3
  • Healthy Participants
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for receipt of Study Drug:

  1. Male or female.
  2. 18 to 55 years of age, inclusive, at time of screening.
  3. Healthy on the basis of physical examination, medical history, and vital signs performed at screening.
  4. Healthy on the basis of clinical laboratory tests performed at screening.
  5. Must pass the comprehension assessment indicating that the participant understands the purpose, procedures, and potential risks and benefits of the study, after reading the and after the investigator or designee has provided detailed information on the study and answered the potential participant's questions.
  6. Must have a between 18.0 and 35.0 kg/m2, inclusive.
  7. Must have a normal (ECG, test which displays a person's heartbeat) at screening.
  8. Must have a blood pressure (after lying face up for greater than or equal to 5 minutes) between 90 and 140 mmHg systolic and less than or equal to 90 mmHg diastolic at screening.
  9. Must complete the informed consent process independently and without assistance and sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
  10. All persons of must have a negative pregnancy test at screening.
  11. A volunteer must be:

    1. Not of childbearing potential, or
    2. Of childbearing potential and practicing a highly effective, preferably user independent method of and agrees to remain on a highly effective method while receiving study drug and until 90 days after the last dose of study drug.
  12. A person of childbearing potential must agree not to donate eggs for the purposes of assisted reproduction during the study and for 90 days after the last dose of study drug.
  13. During the study and for 90 days after the last dose of study drug, persons who are having sexual relationships in which their partner may become pregnant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person. Persons who are having sexual relationships in which their partner may become pregnant should also be advised of the benefit for their partner to use a highly effective method of contraception as condoms may break or leak.
  14. A sperm-producing participant must agree not to donate sperm for the purpose of reproduction during the study and for 90 days after the last dose of study drug.
  15. Must be willing and able to adhere to the study requirements and lifestyle restrictions:

    • Do not take any restricted medications/treatments
    • Agree to follow all study requirements
    • No unusual strenuous exercise
    • Must not donate blood or blood products within 6 months after last dose of study drug
    • Must not participate in another study during the study or within 90 days after last dose of study drug
    • Must not travel to any dengue-endemic region (as defined by the United States Centers for Disease Control and Prevention
    • Must limit the use of food or drinks/beverages containing alcohol to the absolute minimum from 48 hours before first dose of study drug until Day 85.
    • Must refrain from consumption of grapefruit or grapefruit juice, energy drinks, excessive use of caffeine from 7 days before first dose of study drug until Day 85
    • May not use drugs of abuse (including amphetamine, barbiturate, cocaine, methadone, and opiates) until 3 weeks after the last dose of study drug.
    • Should not consume any food containing poppy seeds or codeine-containing formulation starting 72 hours before the screening visits and before any visit during the follow-up phase (to avoid a false-positive urine drug test).
    • Should follow the instructions for the timing of the standardized meals
  16. Available for the duration of the study, which is approximately 85 days after injection of the dengue virus.

Exclusion Criteria for receipt of Study Drug:

  1. History of liver or renal impairment; significant cardiac, vascular, pulmonary, gastrointestinal (such as significant diarrhea, constipation lasting greater than 2 days), endocrine, neurologic, hematologic, rheumatologic, neoplastic, , or metabolic disturbances.
  2. Known allergies, , or intolerance to the study drug (JNJ-64281802) or its inactive substances, or an acute, life threatening allergic reaction or swelling following study drug administration.
  3. History of a severe allergic reaction or anaphylaxis (which is a severe, potentially life-threatening allergic reaction).
  4. Taken any substances or therapies that are not allowed before the first dose of study drug.
  5. Received an investigational intervention or participated in another investigational clinical trial (including investigational vaccines) within 6 months before first dose of study drug, or is currently enrolled in an investigational study, or is planning to be enrolled in an investigational study within 90 days after last dose of study drug. With the exception of participation in COVID-19 vaccine trials and receipt COVID-19 vaccines licensed or under Emergency Use Authorization which can be received at any time.
  6. Persons of childbearing potential only: Pregnant as determined by a positive pregnancy blood test, breastfeeding, or planning to become pregnant during the study or within 90 days after last dose of study drug.
  7. Plans to impregnate and help conceive a child during the study or within 90 days after last dose of study drug.
  8. Any condition for which, in the opinion of the study doctor, participation would not be in the best interest of the participant.
  9. Blood test confirming current infection with type 1 or 2 (HIV-1 or HIV-2), virus (HBV), or virus (HCV), or blood test confirming past or current infection with any of the following flaviviruses: dengue, Zika virus (ZIKV), West Nile virus, or St. Louis Encephalitis (SLE) virus or vaccination for dengue, Zika virus, or Japanese Encephalitis virus (JEV) Note: Blood laboratory testing will assess the presence of antibodies at screening.
  10. Recent (in the past 4 weeks) travel to any dengue-endemic region (as defined by the US CDC) or having definite plans to travel to a dengue endemic region, during the study. Potential participants may be eligible for enrollment greater than or equal to 4 weeks after their return from a dengue-endemic region.
  11. Received or plans to receive:

    1. Licensed - within 28 days before first dose of study drug until 28 days after last dose of study drug.
    2. Other licensed (not live) vaccines - within 14 days before first dose of study drug until 14 days after last dose of study drug.
    3. COVID-19 vaccines, either licensed or under EUA, are allowed at any time during the study however every effort will be made to avoid the above windows of time of administration.

    Note: Vaccinations against DENV and Zika virus are not allowed until 90 days after last dose of study drug.

  12. Employee of the study doctor or study site with direct involvement in the proposed study or other studies under the direction of that study doctor or study site, as well as family members of the employees or the investigator.
  13. Any skin disease in the past 6 months, such as active dermatitis, active eczema, drug rash, psoriasis, and urticaria.
  14. Having donated or lost greater than 1 unit of blood (500 mL) within 30 days or greater than 1 unit of plasma (250 mL) within 7 days before first dose of study drug or having the intention to donate blood or blood products during the study and within 6 months after last dose of study drug.
  15. Receipt of blood products within the past 6 months of initiation of study drug or anticipated receipt of any blood products during the 28 days following dengue virus injection.
  16. Known or suspected congenital or acquired immunodeficiency or use of (excluding topical and nasal) or immunosuppressive drugs within 28 days before first dose of study drug until 28 days following the last dose of study drug.

    a. An immunosuppressive dose of corticosteroids is defined as greater than or equal to10 mg prednisone equivalent per day for grater than or equal to 14 days.

  17. Use of any strong cytochrome P450 (CYP) 3A4 inhibitors (eg, clarithromycin, itraconazole), inducers (eg, phenytoin, rifampin), or substrates for CYP3A4 (eg, midazolam, triazolam), CYP2C8 (eg, repaglinide), CYP2C9 (eg, warfarin, tolbutamide), BCRP (eg Pravastatin and folic acid), or CYP2C19 (eg, S-mephenytoin, omeprazole) within 14 days before first dose of study drug. Certain other medications are allowed including metformin, levothyroxine, H1 and H2 receptor antagonists, weak CYP3A4 inhibitors, selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, tricyclic anti-depressants, anxiolytics, and benzodiazepines.
  18. Any significant alcohol or drug abuse in the past 12 months that has caused medical, occupational, or family problems, as indicated by participant history, or positive test result(s) for drugs of abuse (including amphetamine, barbiturate, benzodiazepine, cocaine, methadone, and opiates) at screening.
  19. Behavioral, cognitive, or psychiatric disease that affects the subject's ability to understand and cooperate with the requirements of the study protocol.
  20. Severe asthma (emergency room visit or hospitalization within the last 6 months).
  21. Asplenia (the absence of a spleen).
  22. Refusal to allow specimen storage for future research.
  23. History of risk factors for life-threatening heart rhythm disturbance which includes heart failure, low potassium levels in the blood, family history of fast, chaotic heartbeats known as Long Syndrome.

Exclusion Criteria for dengue virus injection:

  1. Body temperature greater than or equal to 38.0°C (100.4°F), confirmed by repeat measurements at least 10 minutes after the first measurement.
  2. Acute illness.
  3. Any other clinical or laboratory finding that would exclude the participant from inoculation (including, but limited to, a positive urine/serum pregnancy test), as assessed by the study doctor.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Cohort 1 - Group 1 JNJ High Dose

    Sentinel high-dose. Four participants will be enrolled in Group 1a before enrolling the remaining participants to Group 1b (12 participants total in Group 1, all same dosing regimen). Note group 1a and group 1b are combined into one arm, because the dosing regimen is the same and they were not separated during final statistical analysis.

    Drug: Cohort 1 - Group 1 JNJ High Dose

  • Experimental
    Cohort 1 - Group 2 JNJ Medium Dose

    Group 2 includes Medium and low dose, 14 participants total. Enrolled after completion of Group 1a.

    Drug: Cohort 1 - Group 2 JNJ Medium Dose

  • Experimental
    Cohort 1 - Group 2 JNJ Low Dose

    Group 2 includes Medium and low dose, 14 participants total. Enrolled after completion of Group 1a.

    Drug: Cohort 1 - Group 2 JNJ Low Dose

  • Placebo comparator
    Cohort 1 - Group 1/2 Placebo

    Matching placebo. Note Group 1 placebo and group 2 placebo are combined per sponsor data analysis.

    Drug: Cohort 1 - Group 1/2 Placebo

Interventions

  • DrugCohort 1 - Group 1 JNJ High Dose

    High dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days

    Also known as: JNJ-64281802 (Sentinel high dose)

  • DrugCohort 1 - Group 2 JNJ Medium Dose

    Medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days

    Also known as: JNJ-64281802 (medium dose)

  • DrugCohort 1 - Group 2 JNJ Low Dose

    Low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days

    Also known as: JNJ-64281802 (low dose)

  • DrugCohort 1 - Group 1/2 Placebo

    Matching placebo. Note Group 1 placebo and group 2 placebo are combined per sponsor data analysis.

    Also known as: Placebo High Dose

06

What researchers measure

Primary outcomes

  1. Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection.

    Area under the DENV-3 RNA viral load (VL) concentration-time curves from immediately before inoculation (baseline on Day 1) until Day 29. Notes: * Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/days1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml * Least square differences are calculated versus Placebo

    Time frame: Day1-29

Secondary outcomes

  1. Number of Adverse Events to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

    Overall Summary of Treatment-emergent Adverse Events. Notes: * Overall phase=Pre-challenge+challenge+follow-up phases. * Solicited Systemic Reactogenicity AEs reported in the pre-challenge or follow-up phase are included.

    Time frame: through study completion (Day 120)

  2. Number of Subjects With Treatment-emergent AE's on JNJ64281802 That Are Appreciable/Observable on Physical Exam and Considered Related to Study Treatment.

    * Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. * Adverse events are coded using MedDRA Version 25.0. * Related: Definitely related; Probably related; Possibly related. Not Related: Unlikely related; Unrelated. * Overall phase=Pre-challenge+challenge+follow-up phases. * Solicited Systemic Reactogenicity AEs reported in the pre-challenge or follow-up phase are included.

    Time frame: through study completion (Day 120)

  3. Recording of Vital Signs to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802)-Number of Subjects With Treatment-Emergent Abnormalities and Worst Graded Abnormalities Per Vital Sign Parameter.

    Pulse (bpm), systolic and diastolic blood pressure (mmHg) measured on each clinic visit. -Subjects are counted only at the worst grade

    Time frame: through study completion (Day 120)

  4. 12-lead ECG With Measurement of QTcF to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

    Number of participants with AE of prolonged QTcF.

    Time frame: through study completion (Day 120)

  5. 12-lead ECG With Measurement of QRS Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

    Number of participants with AE of prolonged QRS interval.

    Time frame: through study completion (Day 120)

  6. 12-lead ECG With Measurement of PR Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

    Number of participants with AE of prolonged PR interval.

    Time frame: through study completion (Day 120)

  7. Clinical Laboratory Assessments to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

    Number of participants with treatment-emergent adverse events in laboratory assessments on JNJ 64281802

    Time frame: through study completion (Day 120)

  8. Assess the Dengue Infection-associated Adverse Events (Unwanted Medical Occurrence).

    Number of Subjects with DENV-3 Infection-Associated AEs by Preferred Term and Severity - Solicited Systemic Reactogenicity Notes: - Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. The event experienced by the subject with the worst severity is used. If a subject has missing severity for a specific adverse event, the subject is only counted in the total column for that adverse event. - Adverse events are coded using MedDRA Version 25.0. - Only Solicited Systemic Reactogenicity AEs reported during Challenge Phase are included

    Time frame: Day 1- Day 120

  9. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Area Under the log10-transformed DENV 3 RNA VL Concentration-time Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29 (AUCD1 D29 [log10 VL])

    Notes: - Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/day1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml - One subject in the High Dose Group has a missing sample on Day 29 and is therefore excluded from this analysis since the missing value could not be imputed according to the SAP rules - Least square differences are calculated versus Placebo

    Time frame: Day 1- Day 29

  10. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Peak of Detectable DENV-3 RNA (log10 VL).

    Log10 Peak DENV-3 Viremia (log10 FFU/mL) * Tobit analysis of variance model with log10 Peak DENV-3 Viremia, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 0.18 log10 FFU/ml, with 3.0 FFU/ml the assumed limit of detection (LOD) and values \<LOD are imputed with 1.5 FFU/ml. (FFU=focus forming unit) * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.

    Time frame: through study completion (Day 120)

  11. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo for Duration in Days of Detectable DENV-3 RNA.

    Duration of detectable DENV-3 RNA = Maximum day of (days with detectable DENV-3 RNA) - Minimum day of (days with detectable DENV-3 RNA) +1

    Time frame: Day 1 - Day 120

  12. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Time to First Onset by Days of Detectable DENV 3 RNA.

    Time to first onset of detectable DENV-3 RNA is defined as the number of days between the date of inoculation and the date of the first onset of detectable DENV-3 RNA+1. If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Proportions are calculated with the number of subjects in each treatment arm as denominator.

    Time frame: Day 1- Day 120

  13. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Based on Presence of Detectable DENV-3 RNA as Measured by PCR (log10 VL) or Culture (log10 VL).

    Number of participants with detectable DENV-3 viremia (defined as detectable DENV-3 Viremia result on at least 1 assessment in Study Days 1-29).

    Time frame: Study Days 1- 29

  14. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Area Under the Infectious Viremia Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29.

    \- Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/day1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml

    Time frame: Study Days 1-29

  15. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Area Under the log10-transformed Viremia Curves.

    Tobit Regression Results of Log10 AUC DENV-3 Viremia (log10 FFU/mL/day1-29). FFU = focus forming unit.

    Time frame: Days 1-29

  16. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Peak of Detectable Viremia Level

    * Tobit analysis of variance model with log10 Peak DENV-3 Viremia, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 0.18 log10 FFU/ml, with 3.0 FFU/ml the assumed limit of detection (LOD) and values \<LOD are imputed with 1.5 FFU/ml. FFU = focus-forming unit. * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.

    Time frame: through study completion (Day 120)

  17. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Duration of Detectable Viremia.

    * Duration of detectable DENV-3 Viremia = Maximum day of (days with detectable DENV-3 Viremia) * Minimum day of (days with detectable DENV-3 Viremia) +1 * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.

    Time frame: through study completion (Day 120)

  18. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Time to First Onset of Detectable Viremia.

    Notes: * Time to first onset of detectable DENV-3 viremia is defined as the number of days between the date of inoculation and the date of the first onset of detectable DENV-3 viremia +1. * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result.

    Time frame: Day 1-Day 120

  19. Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Presence of Detectable Viremia.

    \- Presence of detectable DENV-3 Viremia is defined as detectable DENV-3 Viremia result on at least 1 assessment in Study Days 1-29 - Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.

    Time frame: Study Day 1-29

  20. Assess How the Body Handles the Study Drug (JNJ-64281802) Following Repeated Oral Dosing- Maximum Observed Analyte Concentration (Cmax) During Inpatient Stay

    Blood samples will be taken for measurement of plasma concentrations of JNJ-64281802 at specific time points in the study. Additional PK sampling may be performed on the non-intensive PK days (eg, in the event of an overdose) on other time points, in consultation with the JNJ drug development team. Plasma samples will be analyzed to determine concentrations of JNJ-64281802 using a validated, specific, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method under the supervision of the DDT's Bioanalytical Laboratory Department of Bioanalysis.

    Time frame: Loading dose timeframe (inpatient stay): 5 days of loading dose for Cohort 1 and 2 days of loading dose for Cohort 2

  21. Cmax: Maximum Observed Analyte Concentration of JNJ-64281802

    Cmax: maximum observed analyte concentration during maintenance dose phase in ng/mL

    Time frame: Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)

  22. Cmin: Minimum Observed Analyte Concentration of JNJ-64281802

    Cmin: Minimum observed analyte concentration in ng/mL

    Time frame: Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)

  23. Ctrough: Observed Analyte Concentration Just Before the Beginning or at the End of a Dosing Interval of JNJ-64281802

    Ctrough: observed analyte concentration just prior to the beginning or at the end of a dosing interval in ng/mL

    Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)

  24. Cavg: Average Analyte Concentration Over the Dosing Interval (τ) Calculated as AUCτ/τ of JNJ-64281802

    Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)

  25. Tmax: the Actual Sampling Time (in Hours) to Reach the Maximum Observed Analyte Concentration of JNJ-64281802

    Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)

  26. Fluctuation Index (FI): Percentage Fluctuation (Variation) Between Maximum and Minimum Analyte Concentration at Steady-state, Calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-64281802

    Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)

  27. AUCτ: Area Under the Plasma Concentration-time Curve During the Dosing Interval (t Hours); Calculated by Linear-linear Trapezoidal Summation of JNJ-64281802

    Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2, Group 3); Day 15 (Cohort 2, Groups 4 & 5)

  28. Occurrence of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.

    Number of participants with anti-DENV-3 total IgM antibody titers (Occurrence of anti-DENV IgM is defined as a ratio against positive control of IgM antibodies (\>= 1.1) at any timepoint post-baseline)

    Time frame: through study completion (Day 120)

  29. Magnitude of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.

    Peak Anti-DENV IgG Antibodies (U/mL)

    Time frame: through study completion (Day 120)

  30. Time to First Onset of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.

    If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Time to first onset of detectable anti-DENV IgM antibodies is defined as the number of days between the date of inoculation and the date of the first onset of positive anti-DENV IgM antibodies +1.

    Time frame: through study completion (Day 120)

  31. Time to First Onset of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.

    If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Time to first onset of detectable anti-DENV IgG antibodies is defined as the number of days between the date of inoculation and the date of the first onset of positive anti-DENV IgG antibodies +1.

    Time frame: through study completion (Day 120)

07

Results

Posted Apr 24, 2025

Participant flow

The study follows an adaptive 2-stage design consisting of 2 cohorts enrolled in a staggered manner. Unblinded interim analysis of Cohort 1 was performed to determine the dosing regimens for Cohort 2 and provided results for the primary outcome.

Participant flow — Overall Study
MilestoneCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 1/2 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseCohort 2 - Group 3,4,5 Placebo
Started116686766
Completed106676766
Not completed10010000
Withdrew: Withdrawal by subject10000000
Withdrew: Adverse event00010000

Outcome measures

PrimaryAssess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection.

Area under the DENV-3 RNA viral load (VL) concentration-time curves from immediately before inoculation (baseline on Day 1) until Day 29. Notes: * Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/days1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml * Least square differences are calculated versus Placebo

Time frame:
Day1-29
Reported as:
Least squares mean · Log10 AUC VL (log10 copies/mL/28days)
Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection.
Log10 AUC VL (log10 copies/mL/28days)Cohort 1 - Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 Group 2 - JNJ Low DoseCohort 1 Group 2 - JNJ Medium DoseCohort 1 Group 1 - JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 Group 3 - JNJ Daily DoseCohort 2 Group 4 - JNJ Weekly High DoseCohort 2 Group 5 - JNJ Weekly Low Dose
Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection.5.01 (4.40 to 5.62)5.20 (4.55 to 5.86)4.71 (4.05 to 5.38)2.98 (2.38 to 3.59)5.20 (4.34 to 6.05)2.50 (1.43 to 3.56)1.87 (0.59 to 3.15)1.67 (0.34 to 2.99)
SecondaryNumber of Adverse Events to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

Overall Summary of Treatment-emergent Adverse Events. Notes: * Overall phase=Pre-challenge+challenge+follow-up phases. * Solicited Systemic Reactogenicity AEs reported in the pre-challenge or follow-up phase are included.

Time frame:
through study completion (Day 120)
Reported as:
Count of participants · Participants
Number of Adverse Events to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
ParticipantsCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Participants with 1 or more AE (Any AE)866116676
Participants with 1 or more AE related to study treatment33452103
Participants with 1 or more AE related to inoculation with DENV-355534032
Participants with 1 or more AE leading to discontinuation of any study treatment10000000
Participants with 1 or more AE leading to termination of study participation10000000
Participants with 1 or more AE of Mild severity32253554
Participants with 1 or more AE of Moderate severity44350102
Participants with 1 or more AE of Severe severity10113020
Participants with 1 or more AE of Life-Threatening severity00000000
Participants with 1 or more serious AE10000010
Participants with 1 or more serious AE related to study treatment00000000
Participants with 1 or more serious AE related to inoculation with DENV-300000000
Participants with 1 or more AEs leading to death00000000
Participants with 1 or more related AEs leading to death00000000
SecondaryNumber of Subjects With Treatment-emergent AE's on JNJ64281802 That Are Appreciable/Observable on Physical Exam and Considered Related to Study Treatment.

* Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. * Adverse events are coded using MedDRA Version 25.0. * Related: Definitely related; Probably related; Possibly related. Not Related: Unlikely related; Unrelated. * Overall phase=Pre-challenge+challenge+follow-up phases. * Solicited Systemic Reactogenicity AEs reported in the pre-challenge or follow-up phase are included.

Time frame:
through study completion (Day 120)
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-emergent AE's on JNJ64281802 That Are Appreciable/Observable on Physical Exam and Considered Related to Study Treatment.
ParticipantsCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Number of Subjects With Treatment-emergent AE's on JNJ64281802 That Are Appreciable/Observable on Physical Exam and Considered Related to Study Treatment.00000001
SecondaryRecording of Vital Signs to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802)-Number of Subjects With Treatment-Emergent Abnormalities and Worst Graded Abnormalities Per Vital Sign Parameter.

Pulse (bpm), systolic and diastolic blood pressure (mmHg) measured on each clinic visit. -Subjects are counted only at the worst grade

Time frame:
through study completion (Day 120)
Reported as:
Number · participants
Recording of Vital Signs to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802)-Number of Subjects With Treatment-Emergent Abnormalities and Worst Graded Abnormalities Per Vital Sign Parameter.
participantsCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Tachycardia (Grade 1)00010020
Diastolic Blood Pressure Hypertension (Grade 1)00031011
Systolic Blood Pressure Hypertension (Grade 3)00010000
Systolic Blood Pressure Hypertension (Grade 1)01101111
Bradycardia (Grade 1)00001011
Bradycardia (Grade 2)00001020
Bradycardia (Grade 3)00000100
Diastolic Blood Pressure Hypertension (Grade 2)00001000
Diastolic Blood Pressure Hypertension (Grade 3)00000010
Systolic Blood Pressure Hypotension (Grade 1)00000100
Systolic Blood Pressure Hypotension (Grade 2)00000001
Secondary12-lead ECG With Measurement of QTcF to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

Number of participants with AE of prolonged QTcF.

Time frame:
through study completion (Day 120)
Reported as:
Count of participants · Participants
12-lead ECG With Measurement of QTcF to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
ParticipantsCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseCohort 2 - Group 3, Group 4, and Group 5 Placebo
12-lead ECG With Measurement of QTcF to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).00000000
Secondary12-lead ECG With Measurement of QRS Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

Number of participants with AE of prolonged QRS interval.

Time frame:
through study completion (Day 120)
Reported as:
Count of participants · Participants
12-lead ECG With Measurement of QRS Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
ParticipantsCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseCohort 2 - Group 3, Group 4, and Group 5 Placebo
12-lead ECG With Measurement of QRS Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).00000000
Secondary12-lead ECG With Measurement of PR Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

Number of participants with AE of prolonged PR interval.

Time frame:
through study completion (Day 120)
Reported as:
Count of participants · Participants
12-lead ECG With Measurement of PR Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
ParticipantsCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseCohort 2 - Group 3, Group 4, and Group 5 Placebo
12-lead ECG With Measurement of PR Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).00000000
SecondaryClinical Laboratory Assessments to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).

Number of participants with treatment-emergent adverse events in laboratory assessments on JNJ 64281802

Time frame:
through study completion (Day 120)
Reported as:
Count of participants · Participants
Clinical Laboratory Assessments to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
ParticipantsCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Hemoglobin Decreased01033012
AST increased10000111
Hyperglycemia10111031
SecondaryAssess the Dengue Infection-associated Adverse Events (Unwanted Medical Occurrence).

Number of Subjects with DENV-3 Infection-Associated AEs by Preferred Term and Severity - Solicited Systemic Reactogenicity Notes: - Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. The event experienced by the subject with the worst severity is used. If a subject has missing severity for a specific adverse event, the subject is only counted in the total column for that adverse event. - Adverse events are coded using MedDRA Version 25.0. - Only Solicited Systemic Reactogenicity AEs reported during Challenge Phase are included

Time frame:
Day 1- Day 120
Reported as:
Count of participants · Participants
Assess the Dengue Infection-associated Adverse Events (Unwanted Medical Occurrence).
ParticipantsCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Fever — N/a765115666
Fever — Mild10001010
Fever — Moderate00100000
Headache — N/a20371253
Headache — Mild44235323
Headache — Moderate22110100
Maculopapular rash — N/a11282565
Maculopapular rash — Mild63333111
Maculopapular rash — Moderate12101000
Myalgia — N/a513112556
Myalgia — Mild34202120
Myalgia — Moderate01102000
Arthralgia — N/a645102556
Arthralgia — Mild21002120
Arthralgia — Moderate01112000
Retro-orbital pain — N/a534113376
Retro-orbital pain — Mild23203300
Retro-orbital pain — Moderate10000000
Fatigue — N/a32581443
Fatigue — Mild42135133
Fatigue — Moderate12000100
Nausea — N/a635105554
Nausea — Mild22111112
Nausea — Moderate01000010
Abdominal pain — N/a735115575
Abdominal pain — Mild12101101
Abdominal pain — Moderate01000000
Vomiting — N/a656115666
Vomiting — Mild21001000
Vomiting — Moderate00000010
Diarrhea — N/a746115434
Diarrhea — Mild12001232
Diarrhea — Moderate00000010
Decreased appetite — N/a554114564
Decreased appetite — Mild31202112
Decreased appetite — Moderate00000000
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Area Under the log10-transformed DENV 3 RNA VL Concentration-time Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29 (AUCD1 D29 [log10 VL])

Notes: - Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/day1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml - One subject in the High Dose Group has a missing sample on Day 29 and is therefore excluded from this analysis since the missing value could not be imputed according to the SAP rules - Least square differences are calculated versus Placebo

Time frame:
Day 1- Day 29
Reported as:
Least squares mean · log10 copies/ml/28days
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Area Under the log10-transformed DENV 3 RNA VL Concentration-time Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29 (AUCD1 D29 [log10 VL])
log10 copies/ml/28daysCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Area Under the log10-transformed DENV 3 RNA VL Concentration-time Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29 (AUCD1 D29 [log10 VL])2.98 (2.38 to 3.59)4.71 (4.05 to 5.38)5.2 (4.55 to 5.86)5.01 (4.4 to 5.62)5.2 (4.34 to 6.05)2.5 (1.43 to 3.56)1.87 (0.59 to 3.15)1.67 (0.34 to 2.99)
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Peak of Detectable DENV-3 RNA (log10 VL).

Log10 Peak DENV-3 Viremia (log10 FFU/mL) * Tobit analysis of variance model with log10 Peak DENV-3 Viremia, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 0.18 log10 FFU/ml, with 3.0 FFU/ml the assumed limit of detection (LOD) and values \<LOD are imputed with 1.5 FFU/ml. (FFU=focus forming unit) * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.

Time frame:
through study completion (Day 120)
Reported as:
Least squares mean · Log10 Peak DENV-3 Viremia (log10 FFU/mL)
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Peak of Detectable DENV-3 RNA (log10 VL).
Log10 Peak DENV-3 Viremia (log10 FFU/mL)Cohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Peak of Detectable DENV-3 RNA (log10 VL).1.70 (1.01 to 2.4)2.11 (1.36 to 2.87)1.46 (0.68 to 2.24)0.18 (-0.56 to 9.92)2.13 (1.34 to 2.91)-0.98 (-2.27 to 0.31)-0.37 (-1.52 to 0.79)NA (NA to NA)
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo for Duration in Days of Detectable DENV-3 RNA.

Duration of detectable DENV-3 RNA = Maximum day of (days with detectable DENV-3 RNA) - Minimum day of (days with detectable DENV-3 RNA) +1

Time frame:
Day 1 - Day 120
Reported as:
Mean · Days
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo for Duration in Days of Detectable DENV-3 RNA.
DaysCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo for Duration in Days of Detectable DENV-3 RNA.1.40 ± 2.3661.33 ± 1.3664.67 ± 2.6583.86 ± 1.0697.5 ± 1.7612.67 ± 4.1311.33 ± 3.2661 ± 2.449
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Time to First Onset by Days of Detectable DENV 3 RNA.

Time to first onset of detectable DENV-3 RNA is defined as the number of days between the date of inoculation and the date of the first onset of detectable DENV-3 RNA+1. If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Proportions are calculated with the number of subjects in each treatment arm as denominator.

Time frame:
Day 1- Day 120
Reported as:
Median · Days to first onset of detectable DENV-3
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Time to First Onset by Days of Detectable DENV 3 RNA.
Days to first onset of detectable DENV-3Cohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Time to First Onset by Days of Detectable DENV 3 RNA.3 (2 to NA)5 (5 to NA)11 (5 to NA)NA (7 to NA)4 (4 to NA)NA (8 to NA)NA (8 to NA)NA (15 to NA)
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Based on Presence of Detectable DENV-3 RNA as Measured by PCR (log10 VL) or Culture (log10 VL).

Number of participants with detectable DENV-3 viremia (defined as detectable DENV-3 Viremia result on at least 1 assessment in Study Days 1-29).

Time frame:
Study Days 1- 29
Reported as:
Count of participants · Participants
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Based on Presence of Detectable DENV-3 RNA as Measured by PCR (log10 VL) or Culture (log10 VL).
ParticipantsCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Based on Presence of Detectable DENV-3 RNA as Measured by PCR (log10 VL) or Culture (log10 VL).34676110
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Area Under the Infectious Viremia Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29.

\- Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/day1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml

Time frame:
Study Days 1-29
Reported as:
Least squares mean · log10 copies/ml/28days
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Area Under the Infectious Viremia Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29.
log10 copies/ml/28daysCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Area Under the Infectious Viremia Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29.2.98 (2.38 to 3.59)4.71 (4.05 to 5.38)5.20 (4.55 to 5.86)5.01 (4.40 to 5.62)5.20 (4.34 to 6.05)2.50 (1.43 to 3.56)1.87 (0.59 to 3.15)1.67 (0.34 to 2.99)
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Area Under the log10-transformed Viremia Curves.

Tobit Regression Results of Log10 AUC DENV-3 Viremia (log10 FFU/mL/day1-29). FFU = focus forming unit.

Time frame:
Days 1-29
Reported as:
Least squares mean · log10 FFU/mL/day
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Area Under the log10-transformed Viremia Curves.
log10 FFU/mL/dayCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Area Under the log10-transformed Viremia Curves.1.57 (1.11 to 2.03)2.38 (1.90 to 2.87)2.63 (2.16 to 3.09)2.37 (1.94 to 2.80)2.68 (2.22 to 3.14)0.86 (0.09 to 1.64)1.28 (0.60 to 1.96)NA (NA to NA)
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Peak of Detectable Viremia Level

* Tobit analysis of variance model with log10 Peak DENV-3 Viremia, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 0.18 log10 FFU/ml, with 3.0 FFU/ml the assumed limit of detection (LOD) and values \<LOD are imputed with 1.5 FFU/ml. FFU = focus-forming unit. * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.

Time frame:
through study completion (Day 120)
Reported as:
Least squares mean · log10 FFU/ml
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Peak of Detectable Viremia Level
log10 FFU/mlCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Peak of Detectable Viremia Level0.18 (-0.56 to 0.92)1.46 (0.68 to 2.24)2.11 (1.36 to 2.87)1.70 (1.01 to 2.40)2.13 (1.34 to 2.91)-0.98 (-2.27 to 0.31)-0.37 (-1.52 to 0.79)NA (NA to NA)
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Duration of Detectable Viremia.

* Duration of detectable DENV-3 Viremia = Maximum day of (days with detectable DENV-3 Viremia) * Minimum day of (days with detectable DENV-3 Viremia) +1 * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.

Time frame:
through study completion (Day 120)
Reported as:
Mean · Days
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Duration of Detectable Viremia.
DaysCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Duration of Detectable Viremia.1.40 ± 2.3661.33 ± 1.3664.67 ± 2.6583.86 ± 1.0697.50 ± 1.7612.67 ± 4.1311.33 ± 3.2661.00 ± 2.449
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Time to First Onset of Detectable Viremia.

Notes: * Time to first onset of detectable DENV-3 viremia is defined as the number of days between the date of inoculation and the date of the first onset of detectable DENV-3 viremia +1. * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result.

Time frame:
Day 1-Day 120
Reported as:
Median · Days to onset of DENV-3 RNA Viremia
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Time to First Onset of Detectable Viremia.
Days to onset of DENV-3 RNA ViremiaCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Time to First Onset of Detectable Viremia.5.00 (5.00 to NA)7.50 (7.00 to NA)16.00 (9.00 to NA)NA (9.00 to NA)6.00 (4.00 to NA)NA (11.00 to NA)NA (11.00 to NA)—
SecondaryAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Presence of Detectable Viremia.

\- Presence of detectable DENV-3 Viremia is defined as detectable DENV-3 Viremia result on at least 1 assessment in Study Days 1-29 - Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.

Time frame:
Study Day 1-29
Reported as:
Count of participants · Participants
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Presence of Detectable Viremia.
ParticipantsCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Presence of Detectable Viremia.34676110
SecondaryAssess How the Body Handles the Study Drug (JNJ-64281802) Following Repeated Oral Dosing- Maximum Observed Analyte Concentration (Cmax) During Inpatient Stay

Blood samples will be taken for measurement of plasma concentrations of JNJ-64281802 at specific time points in the study. Additional PK sampling may be performed on the non-intensive PK days (eg, in the event of an overdose) on other time points, in consultation with the JNJ drug development team. Plasma samples will be analyzed to determine concentrations of JNJ-64281802 using a validated, specific, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method under the supervision of the DDT's Bioanalytical Laboratory Department of Bioanalysis.

Time frame:
Loading dose timeframe (inpatient stay): 5 days of loading dose for Cohort 1 and 2 days of loading dose for Cohort 2
Reported as:
Mean · Cmax (ng/mL)
Assess How the Body Handles the Study Drug (JNJ-64281802) Following Repeated Oral Dosing- Maximum Observed Analyte Concentration (Cmax) During Inpatient Stay
Cmax (ng/mL)Cohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Assess How the Body Handles the Study Drug (JNJ-64281802) Following Repeated Oral Dosing- Maximum Observed Analyte Concentration (Cmax) During Inpatient Stay1259 ± 337553 ± 232104 ± 55.12141 ± 10511894 ± 8661187 ± 335
SecondaryCmax: Maximum Observed Analyte Concentration of JNJ-64281802

Cmax: maximum observed analyte concentration during maintenance dose phase in ng/mL

Time frame:
Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)
Reported as:
Mean · Cmax (ng/mL)
Cmax: Maximum Observed Analyte Concentration of JNJ-64281802
Cmax (ng/mL)Cohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Cmax: Maximum Observed Analyte Concentration of JNJ-642818023242 ± 474882 ± 198162 ± 9.295245 ± 17455410 ± 18542826 ± 843
SecondaryCmin: Minimum Observed Analyte Concentration of JNJ-64281802

Cmin: Minimum observed analyte concentration in ng/mL

Time frame:
Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)
Reported as:
Mean · ng/mL
Cmin: Minimum Observed Analyte Concentration of JNJ-64281802
ng/mLCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Cmin: Minimum Observed Analyte Concentration of JNJ-642818022438 ± 391608 ± 169106 ± 23.53845 ± 15201455 ± 310989 ± 463
SecondaryCtrough: Observed Analyte Concentration Just Before the Beginning or at the End of a Dosing Interval of JNJ-64281802

Ctrough: observed analyte concentration just prior to the beginning or at the end of a dosing interval in ng/mL

Time frame:
Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
Reported as:
Mean · ng/mL
Ctrough: Observed Analyte Concentration Just Before the Beginning or at the End of a Dosing Interval of JNJ-64281802
ng/mLCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Ctrough: Observed Analyte Concentration Just Before the Beginning or at the End of a Dosing Interval of JNJ-642818022549 ± 344628 ± 190112 ± 26.94027 ± 11661500 ± 3561228 ± 449
SecondaryCavg: Average Analyte Concentration Over the Dosing Interval (τ) Calculated as AUCτ/τ of JNJ-64281802
Time frame:
Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
Reported as:
Mean · ng/mL
Cavg: Average Analyte Concentration Over the Dosing Interval (τ) Calculated as AUCτ/τ of JNJ-64281802
ng/mLCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Cavg: Average Analyte Concentration Over the Dosing Interval (τ) Calculated as AUCτ/τ of JNJ-642818022947 ± 504743 ± 168133 ± 15.44717 ± 14672502 ± 6781571 ± 528
SecondaryTmax: the Actual Sampling Time (in Hours) to Reach the Maximum Observed Analyte Concentration of JNJ-64281802
Time frame:
Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
Reported as:
Median · hours
Tmax: the Actual Sampling Time (in Hours) to Reach the Maximum Observed Analyte Concentration of JNJ-64281802
hoursCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Tmax: the Actual Sampling Time (in Hours) to Reach the Maximum Observed Analyte Concentration of JNJ-642818028.03 (8.00 to 12.10)8.03 (8.00 to 8.63)8.05 (6.02 to 8.45)8.01 (4.00 to 12.07)4.01 (4.00 to 4.02)8.07 (4.00 to 12.03)
SecondaryFluctuation Index (FI): Percentage Fluctuation (Variation) Between Maximum and Minimum Analyte Concentration at Steady-state, Calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-64281802
Time frame:
Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
Reported as:
Mean · % fluctuation
Fluctuation Index (FI): Percentage Fluctuation (Variation) Between Maximum and Minimum Analyte Concentration at Steady-state, Calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-64281802
% fluctuationCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Fluctuation Index (FI): Percentage Fluctuation (Variation) Between Maximum and Minimum Analyte Concentration at Steady-state, Calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-6428180227.5 ± 4.6338.4 ± 17.143.6 ± 16.332.7 ± 20.0155 ± 38.1122 ± 25.1
SecondaryAUCτ: Area Under the Plasma Concentration-time Curve During the Dosing Interval (t Hours); Calculated by Linear-linear Trapezoidal Summation of JNJ-64281802
Time frame:
Day 21 (Cohort 1); Day 21 (Cohort 2, Group 3); Day 15 (Cohort 2, Groups 4 & 5)
Reported as:
Mean · ng.h/mL
AUCτ: Area Under the Plasma Concentration-time Curve During the Dosing Interval (t Hours); Calculated by Linear-linear Trapezoidal Summation of JNJ-64281802
ng.h/mLCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
AUCτ: Area Under the Plasma Concentration-time Curve During the Dosing Interval (t Hours); Calculated by Linear-linear Trapezoidal Summation of JNJ-6428180270717 ± 1209317821 ± 40283186 ± 369113216 ± 35203420271 ± 113827263861 ± 88651
SecondaryOccurrence of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.

Number of participants with anti-DENV-3 total IgM antibody titers (Occurrence of anti-DENV IgM is defined as a ratio against positive control of IgM antibodies (\>= 1.1) at any timepoint post-baseline)

Time frame:
through study completion (Day 120)
Reported as:
Count of participants · Participants
Occurrence of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.
ParticipantsCohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Occurrence of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.44676211
SecondaryMagnitude of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.

Peak Anti-DENV IgG Antibodies (U/mL)

Time frame:
through study completion (Day 120)
Reported as:
Mean · Peak Anti-DENV Ig Antibodies (U/mL)
Magnitude of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.
Peak Anti-DENV Ig Antibodies (U/mL)Cohort 1 - Group 1 JNJ High DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 2 JNJ Low DoseCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Magnitude of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.14.25 ± 16.17727.97 ± 33.31167.27 ± 65.53471.97 ± 43.603151.57 ± 55.68347.21 ± 66.33416.32 ± 35.8294.79 ± 6.804
SecondaryTime to First Onset of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.

If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Time to first onset of detectable anti-DENV IgM antibodies is defined as the number of days between the date of inoculation and the date of the first onset of positive anti-DENV IgM antibodies +1.

Time frame:
through study completion (Day 120)
Reported as:
Median · Days
Time to First Onset of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.
DaysCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Time to First Onset of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.14.00 (13.00 to NA)16.00 (11.00 to NA)26.00 (16.00 to NA)NA (1.00 to NA)14.00 (13.00 to NA)NA (21.00 to NA)NA (18.00 to NA)NA (33.00 to NA)
SecondaryTime to First Onset of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.

If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Time to first onset of detectable anti-DENV IgG antibodies is defined as the number of days between the date of inoculation and the date of the first onset of positive anti-DENV IgG antibodies +1.

Time frame:
through study completion (Day 120)
Reported as:
Median · Days
Time to First Onset of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.
DaysCohort 1 Group 1 Placebo and Cohort 1 Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4, and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly Dose
Time to First Onset of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.21.00 (13.00 to 21.00)26.00 (16.00 to NA)NA (23.00 to NA)NA (23.00 to NA)16.50 (11.00 to NA)NA (29.00 to NA)NA (85.00 to NA)—

Adverse events

Collected over Adverse event data was collected for the duration of the enrollment period (90 days total for Cohort 1; 122 days total for Cohort 2) in relation to baseline. Subjects began the study drug (or placebo) on Day -5 (Cohort 1) or Day -2 (Cohort 2) followed by challenge with DENV-3 on Day 1. Subjects were followed for AE's through completion of enrollment at Day 85 (Cohort 1) or Day 120 (Cohort 2).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Cohort 10/8 (0%)1/8 (12.5%)8/8 (100%)
JNJ-64281802 Low Dose0/6 (0%)0/6 (0%)6/6 (100%)
JNJ-64281802 Medium Dose0/6 (0%)0/6 (0%)6/6 (100%)
JNJ-64281802 High Dose0/11 (0%)0/11 (0%)11/11 (100%)
Placebo Cohort 20/6 (0%)0/6 (0%)6/6 (100%)
JNJ-64281802 Daily Dose (Cohort 2 Group 3)0/6 (0%)0/6 (0%)6/6 (100%)
JNJ-64281802 Weekly Dose (Cohort 2 Group 4)0/7 (0%)1/7 (14.3%)7/7 (100%)
JNJ-64281802 Weekly Dose (Cohort 2 Group 5)0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventPlacebo Cohort 1JNJ-64281802 Low DoseJNJ-64281802 Medium DoseJNJ-64281802 High DosePlacebo Cohort 2JNJ-64281802 Daily Dose (Cohort 2 Group 3)JNJ-64281802 Weekly Dose (Cohort 2 Group 4)JNJ-64281802 Weekly Dose (Cohort 2 Group 5)
Drug overdosePsychiatric disorders0/80/60/60/110/60/61/70/6
Creatinine Kinase HighMusculoskeletal and connective tissue disorders1/80/60/60/110/60/60/70/6
AST increasedGastrointestinal disorders1/80/60/60/110/60/60/70/6
Most frequent other events
Showing 10 of 93
Most frequent other events
EventPlacebo Cohort 1JNJ-64281802 Low DoseJNJ-64281802 Medium DoseJNJ-64281802 High DosePlacebo Cohort 2JNJ-64281802 Daily Dose (Cohort 2 Group 3)JNJ-64281802 Weekly Dose (Cohort 2 Group 4)JNJ-64281802 Weekly Dose (Cohort 2 Group 5)
Rash Maculo-papular (DENV Infection Associated)Skin and subcutaneous tissue disorders7/85/64/63/114/61/61/71/6
Headache (DENV Infection Associated)General disorders5/84/62/63/115/64/62/73/6
Fatigue (DENV Infection Associated)General disorders5/84/61/63/115/62/63/73/6
Myalgia (DENV Infection Associated)General disorders3/85/63/60/114/61/62/70/6
Vessel Puncture Site BruiseGeneral disorders0/84/63/64/111/61/63/73/6
Diarrhea (DENV Infection Associated)Gastrointestinal disorders1/82/60/60/111/62/64/72/6
Hemoglobin DecreasedInvestigations0/81/60/63/113/60/61/71/6
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/81/60/60/110/61/61/73/6
LymphadenopathyBlood and lymphatic system disorders1/82/63/60/112/60/60/70/6
Eye Pain (DENV Infection Associated)Eye disorders3/83/62/60/113/63/60/70/6

Baseline characteristics

Group 1 Placebo and Group 2 Placebo are combined in one category to be consistent with how data was analyzed. Group 2 placebo were not analyzed on their own (group 1/2 placebos were combined during analysis).

Age, Categorical
Age, Categorical(Participants)Cohort 1 - Group 1 and Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4 and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseTotal
<=18 years000000000
Between 18 and 65 years86611667656
>=65 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - Group 1 and Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4 and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseTotal
Female4457414433
Male4214253223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 - Group 1 and Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4 and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseTotal
Hispanic or Latino100000001
Not Hispanic or Latino75611567653
Unknown or Not Reported010010002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 - Group 1 and Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4 and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseTotal
American Indian or Alaska Native100000001
Asian001100013
Native Hawaiian or Other Pacific Islander000000000
Black or African American3335212019
White3223355528
More than one race100200003
Unknown or Not Reported010010002
Region of Enrollment
Region of Enrollment(participants)Cohort 1 - Group 1 and Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4 and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseTotal
United States86611667656
PRNT (50) DENV
PRNT (50) DENV(participants)Cohort 1 - Group 1 and Group 2 PlaceboCohort 1 - Group 2 JNJ Low DoseCohort 1 - Group 2 JNJ Medium DoseCohort 1 - Group 1 JNJ High DoseCohort 2 - Group 3, Group 4 and Group 5 PlaceboCohort 2 - Group 3 JNJ Daily DoseCohort 2 - Group 4 JNJ Weekly DoseCohort 2 - Group 5 JNJ Weekly DoseTotal
PRNT (50) DENV-1 <=1086611667656
PRNT (50) DENV-2 <=1086611667656
PRNT (50) DENV-3 <=1086611667656
PRNT (50) DENV-4 <=1086611667656
08

Study locations

2 sites
  • Johns Hopkins University, Bloomberg School of Public Health
    Baltimore, Maryland 21202, United States
  • University of Vermont Medical Center (UVMMC), Clinical Research Center
    Burlington, Vermont 05401, United States
09

References and documents

Publications

  • Durbin AP, Van Wesenbeeck L, Pierce KK, Herrera-Taracena G, Ebone L, Buelens A, Lutton P, Sabundayo BP, Van Eygen V, De Clerck K, Fetter I, Voge NV, Fang X, Goeyvaerts N, Vandendijck Y, Mayfield J, Lenz O, De Meyer S, Kakuda TN, He H, Amaro-Carambot E, Akli RD, Carmolli M, De Marez T, Whitehead SS, Van Loock M, Rasschaert F. Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model. N Engl J Med. 2025 Nov 27;393(21):2107-2118. doi: 10.1056/NEJMoa2500179. PubMed 41297006 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in May 2023, 15 months.

Results were first posted in Apr 2025, 1 year 11 months after primary completion.

Of 31 phase 2 interventional studies under Dengue, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 38. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2021
First posted
Sep 17, 2021
StartActual
Feb 3, 2022
Primary completionActual
May 16, 2023
CompletionActual
Sep 10, 2024
Results first posted
Apr 24, 2025
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 4, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameAssess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection.28 days → Day1-29
  • DescriptionAssess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection.: how it is measured was reworded
Nov 4, 2026
Documents
Nov 4, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41297006 ↗
Nov 4, 2026
Secondary outcomes
8 edited, 22 time frame changed, 22 more
What changed in the outcomes
  • EditedPhysical ExaminationsRecording of Vital Signs to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802)-Number of Subjects With Treatment-Emergent Abnormalities and Worst Graded Abnormalities Per Vital Sign Parameter.Time frame: 99 weeks → through study completion (Day 120)
  • EditedAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Peak of Detectable Viremia LevelTime frame: 99 weeks → through study completion (Day 120)
  • EditedAssess How the Body Handles the Study Drug (JNJ-64281802) Following Repeated Oral Dosing. Using Pharmacokinetic Analysis From Repeated Blood Samples Taken at Specified Time Points After Drug Administration- Maximum Observed Analyte Concentration (Cmax) During 2 Inpatient Stays.StayTime frame: 99 weeks → Loading dose timeframe (inpatient stay): 5 days of loading dose for Cohort 1 and 2 days of loading dose for Cohort 2
  • EditedTmax: the Actual Sampling Time (in Hours) to Reach the Maximum Observed Analyte Concentration of JNJ-64281802Time frame: 99 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
  • EditedFluctuation Index (FI): Percentage Fluctuation (Variation) Between Maximum and Minimum Analyte Concentration at Steady-state, Calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-64281802Time frame: 99 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
  • EditedOccurrence and Magnitude of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.Time frame: 99 weeks → through study completion (Day 120)
  • EditedOccurrence and Magnitude of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.Time frame: 99 weeks → through study completion (Day 120)
  • ChangedBefore Recording of Vital Signs to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).Now Number of Subjects With Treatment-emergent AE's on JNJ64281802 That Are Appreciable/Observable on Physical Exam and Considered Related to Study Treatment.Time frame: 99 weeks → through study completion (Day 120)
  • Time frameNumber of Adverse Events to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).85 Days → through study completion (Day 120)
  • Time frame12-lead ECG With Measurement of QTcF to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).99 weeks → through study completion (Day 120)
  • Time frame12-lead ECG With Measurement of QRS Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).99 weeks → through study completion (Day 120)
  • Time frame12-lead ECG With Measurement of PR Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).99 weeks → through study completion (Day 120)
  • Time frameClinical Laboratory Assessments to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).99 weeks → through study completion (Day 120)
  • Time frameAssess the Dengue Infection-associated Adverse Events (Unwanted Medical Occurrence).99 weeks → Day 1- Day 120
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Area Under the log10-transformed DENV 3 RNA VL Concentration-time Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29 (AUCD1 D29 [log10 VL])99 weeks → Day 1- Day 29
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Peak of Detectable DENV-3 RNA (log10 VL).99 weeks → through study completion (Day 120)
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo for Duration in Days of Detectable DENV-3 RNA.99 weeks → Day 1 - Day 120
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Time to First Onset by Days of Detectable DENV 3 RNA.99 weeks → Day 1- Day 120
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Based on Presence of Detectable DENV-3 RNA as Measured by PCR (log10 VL) or Culture (log10 VL).99 weeks → Study Days 1- 29
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Area Under the Infectious Viremia Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29.99 weeks → Study Days 1-29
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Area Under the log10-transformed Viremia Curves.99 weeks → Days 1-29
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Duration of Detectable Viremia.99 weeks → through study completion (Day 120)
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Time to First Onset of Detectable Viremia.99 weeks → Day 1-Day 120
  • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Presence of Detectable Viremia.99 weeks → Study Day 1-29
  • Time frameCmax: Maximum Observed Analyte Concentration of JNJ-6428180299 weeks → Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)
  • Time frameCmin: Minimum Observed Analyte Concentration of JNJ-6428180299 weeks → Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)
  • Time frameCtrough: Observed Analyte Concentration Just Before the Beginning or at the End of a Dosing Interval of JNJ-6428180299 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
  • Time frameCavg: Average Analyte Concentration Over the Dosing Interval (τ) Calculated as AUCτ/τ of JNJ-6428180299 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
  • Time frameAUCτ: Area Under the Plasma Concentration-time Curve During the Dosing Interval (t Hours); Calculated by Linear-linear Trapezoidal Summation of JNJ-6428180299 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2, Group 3); Day 15 (Cohort 2, Groups 4 & 5)
  • Time frameTime to First Onset of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.99 weeks → through study completion (Day 120)
  • …and 22 more, on the record history on ClinicalTrials.gov ↗
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Posted results revised
    Documents Informed consent form ↗ posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41297006 ↗
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameAssess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection.28 days → Day1-29
    • DescriptionAssess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection.: how it is measured was reworded
    Secondary outcomes 8 edited, 22 time frame changed, 22 more
    What changed in the outcomes
    • EditedPhysical ExaminationsRecording of Vital Signs to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802)-Number of Subjects With Treatment-Emergent Abnormalities and Worst Graded Abnormalities Per Vital Sign Parameter.Time frame: 99 weeks → through study completion (Day 120)
    • EditedAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Peak of Detectable Viremia LevelTime frame: 99 weeks → through study completion (Day 120)
    • EditedAssess How the Body Handles the Study Drug (JNJ-64281802) Following Repeated Oral Dosing. Using Pharmacokinetic Analysis From Repeated Blood Samples Taken at Specified Time Points After Drug Administration- Maximum Observed Analyte Concentration (Cmax) During 2 Inpatient Stays.StayTime frame: 99 weeks → Loading dose timeframe (inpatient stay): 5 days of loading dose for Cohort 1 and 2 days of loading dose for Cohort 2
    • EditedTmax: the Actual Sampling Time (in Hours) to Reach the Maximum Observed Analyte Concentration of JNJ-64281802Time frame: 99 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
    • EditedFluctuation Index (FI): Percentage Fluctuation (Variation) Between Maximum and Minimum Analyte Concentration at Steady-state, Calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-64281802Time frame: 99 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
    • EditedOccurrence and Magnitude of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.Time frame: 99 weeks → through study completion (Day 120)
    • EditedOccurrence and Magnitude of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.Time frame: 99 weeks → through study completion (Day 120)
    • ChangedBefore Recording of Vital Signs to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).Now Number of Subjects With Treatment-emergent AE's on JNJ64281802 That Are Appreciable/Observable on Physical Exam and Considered Related to Study Treatment.Time frame: 99 weeks → through study completion (Day 120)
    • Time frameNumber of Adverse Events to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).85 Days → through study completion (Day 120)
    • Time frame12-lead ECG With Measurement of QTcF to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).99 weeks → through study completion (Day 120)
    • Time frame12-lead ECG With Measurement of QRS Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).99 weeks → through study completion (Day 120)
    • Time frame12-lead ECG With Measurement of PR Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).99 weeks → through study completion (Day 120)
    • Time frameClinical Laboratory Assessments to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).99 weeks → through study completion (Day 120)
    • Time frameAssess the Dengue Infection-associated Adverse Events (Unwanted Medical Occurrence).99 weeks → Day 1- Day 120
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Area Under the log10-transformed DENV 3 RNA VL Concentration-time Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29 (AUCD1 D29 [log10 VL])99 weeks → Day 1- Day 29
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Peak of Detectable DENV-3 RNA (log10 VL).99 weeks → through study completion (Day 120)
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo for Duration in Days of Detectable DENV-3 RNA.99 weeks → Day 1 - Day 120
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Time to First Onset by Days of Detectable DENV 3 RNA.99 weeks → Day 1- Day 120
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Based on Presence of Detectable DENV-3 RNA as Measured by PCR (log10 VL) or Culture (log10 VL).99 weeks → Study Days 1- 29
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Area Under the Infectious Viremia Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29.99 weeks → Study Days 1-29
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Area Under the log10-transformed Viremia Curves.99 weeks → Days 1-29
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Duration of Detectable Viremia.99 weeks → through study completion (Day 120)
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Time to First Onset of Detectable Viremia.99 weeks → Day 1-Day 120
    • Time frameAntiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Presence of Detectable Viremia.99 weeks → Study Day 1-29
    • Time frameCmax: Maximum Observed Analyte Concentration of JNJ-6428180299 weeks → Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)
    • Time frameCmin: Minimum Observed Analyte Concentration of JNJ-6428180299 weeks → Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)
    • Time frameCtrough: Observed Analyte Concentration Just Before the Beginning or at the End of a Dosing Interval of JNJ-6428180299 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
    • Time frameCavg: Average Analyte Concentration Over the Dosing Interval (τ) Calculated as AUCτ/τ of JNJ-6428180299 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
    • Time frameAUCτ: Area Under the Plasma Concentration-time Curve During the Dosing Interval (t Hours); Calculated by Linear-linear Trapezoidal Summation of JNJ-6428180299 weeks → Day 21 (Cohort 1); Day 21 (Cohort 2, Group 3); Day 15 (Cohort 2, Groups 4 & 5)
    • Time frameTime to First Onset of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.99 weeks → through study completion (Day 120)
    • …and 22 more, on the record history on ClinicalTrials.gov ↗
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05048875
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Feb 3, 2022
Primary completion
May 16, 2023
Completion
Sep 10, 2024
Results posted
Apr 24, 2025
Last update
Nov 4, 2026

Study contacts

Anna Durbin, MD
principal investigator · Center for Immunization Research, Johns Hopkins School of Public Health

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion